From Breakthroughs Blog: Guest Post

 
Neil Palmer/CIAT
Preparing the ground in the Brazilian Amazon for a new antimalarial to reduce relapse

Tackling malaria in the Brazilian Amazon has proved challenging. But furtunetly, a solution could be in sight.

Read More
PATH/Monique Berlier
Ensuring resistance doesn’t take hold: The importance of taking on typhoid now

Typhoid may seem like a distant memory in industrialized countries, but for many low- and middle-income countries it continues to cause millions of illnesses and about 150,000 deaths per year. New tools are needed to combat this looming threat.

Read More
Andrew Loxley, Court
Empowerment—the payoff of new HIV prevention tools for young women

Evidence shows that when women are both empowered and healthy, they are more likely to have healthy families, educate their children, and make positive social and economic contributions to society. New discreet and long-acting HIV prevention tools have the potential to empower women to protect their own health and unlock their potential.

Read More
PATH/Katrina Peach
TB epidemic looms large in era of declining R&D funding

October 2016 delivered two sobering wake-up calls: The tuberculosis (TB) epidemic is larger than many realized, and TB R&D has has fallen to its lowest level in seven years.

Read More
Rob Oxley/DFID
DFID lays out vision to tackle global challenges through investments in research

The United Kingdom’s Department for International Development released it’s first-ever research review, laying out a vision for how it will invest £390 million in research and technology per year over the next four years to tackle the world’s toughest challenges.

PATH
Read More
GHTC/Matthew Robinson
The world commits to the AMR fight

At the United Nations General Assembly, world leaders made an unprecedented collective commitment to fighting the growing problem of antimicrobial resistance. GHTC and Global Health Council analyze what that commitment entails, why it matters, and the importance of what happens next.

Global Health Council
Read More
US Centers for Disease Control and Prevention
New information for innovation: Antimicrobial Resistance Isolate Bank

A new tool from the US Centers for Disease Control and Prevention is helping researchers develop diagnostic tests and antibiotics to combat the growing problem of antibiotic resistance.

Read More
Courtney Carson/GHTC
From DC to Atlanta: Becoming Better Advocates for CDC Global Health Programs on Capitol Hill

Global health advocates traveled to the US Centers for Disease Control and Prevention last month. Here's what they learned about the agency's work.

Global Health Council
Read More
PATH/Evelyn Hockstein
Progress report on health R&D: A Q&A with USAID

USAID's Neal Brandes answers our questions about the agency's latest Health-Related Research and Development Progress Report and USAID's ongoing support for global health R&D.

Read More
Funding by crisis is no cure for global health threats

The Zika virus outbreak reinforces the need for US policymakers to stop funding by crisis and commit to sustainable, long-term investment in global health R&D.

GHTC
Read More
A vaccine is essential to conclusively end HIV/AIDS: New modeling data catalyzes conversations around the end of HIV/AIDS and a vaccine’s role in getting there

In this guest post Tom Harmon, senior policy analyst at the International AIDS Vaccine Initiative (IAVI), highlights a new analysis exploring the critical role of a vaccine in ending AIDS.

Read More
Ebola funding boost hides ongoing decline in neglected disease R&D

In this guest post, Anna Doubell, an analyst at Policy Cures, writes about the findings of this year’s G-FINDER report on neglected disease research and development (R&D). Supporting data from the report was released this week and is now available online through the G-FINDER public search tool.

Policy Cures
Read More
New affordable oral cholera vaccine receives WHO prequalification

In January, GHTC member International Vaccine Institute (IVI) announced that a new oral cholera vaccine it developed in partnership with Korean biotech company EuBiologics, Co. Ltd.—Euvichol®—received prequalification from the World Health Organization (WHO), paving the way for the vaccine to be purchased by global procurement bodies like Gavi, the Vaccine Alliance and UNICEF.

Read More
Welcoming the National Action Plan for Combating Multidrug-Resistant Tuberculosis: Important first steps, critical next steps

In this guest post, Dara Erck, vice president of external affairs at Aeras, discusses the new White House National Action Plan for Combating Multidrug-Resistant Tuberculosis and how it could accelerate research and development (R&D) of new technologies to combat multidrug-resistant TB (MDR-TB).

Aeras
Read More
TB Alliance
Fruit-flavored drugs to saves kids’ lives: First correctly-dosed, child-friendly TB treatments developed

Early this month, GHTC member TB Alliance and its partners announced the creation of the first-ever appropriate, child-friendly tuberculosis (TB) medicine in the correct doses.

TB Alliance
TB Alliance
Read More
A second chance for a TB research movement

In this guest post, Mike Frick, TB/HIV project officer at the Treatment Action Group (TAG), reflects on activist calls for greater investment in tuberculosis (TB) research and development (R&D) at the 46th Union World Conference on Lung Health and the stagnation of global TB R&D funding at a time of growing drug resistance.

Read More
Why we need research to detect, prevent, and ultimately, eliminate parasitic diseases

In this guest post, Dr. Monica Parise—deputy director for program and science—and Dr. Larry Slutsker—director of the Division of Parasitic Disease and Malaria—at the US Centers for Disease Control and Prevention (CDC) Center for Global Health—discuss the role of research in advancing efforts to detect, prevent, and eliminate parasitic diseases.

Read More
New legislation aims to #SaveMomsandKids everywhere

In this guest post, Heather Ignatius—senior policy and advocacy officer at PATH—writes about a new bipartisan piece of legislation to accelerate progress towards ending preventable child and maternal deaths.

PATH
Read More
PATH/Doune Porter
Four reasons to visit the Contraceptive Technology Innovation Exchange today

Over the past several decades, overall investment in contraceptive R&D has declined dramatically. The result? Renewed commitment and partnerships will be required to ensure that new contraceptive methods advance through the development pipeline and that access to the final products is affordable and equitable.

FHI360
Read More
US Centers for Disease Control and Prevention
Fighting for the future: Why we must come together to fight antibiotic resistance around the globe

I am pleased to have the opportunity to write about what is perhaps today’s most vexing public health challenge—the growing threat of antibiotic resistance.

Read More
DNDi/João Roberto Ripper
Chagas disease: A silent kiss and a neglected killer

Valentine’s Day seems like a fitting occasion to shine some needed light on a disease that can begin with a late-night “kiss” but ends with a broken heart.

Read More
The state of reproductive health R&D for developing countries

In this guest post, Dale Halliday—an analyst at Policy Cures—discusses the finding of Policy Cures’ report on funding for reproductive health technology research and development (R&D) in developing countries.

Policy Cures
Read More
#CoughUpTheTBMoney: TB activists call for tripling annual spending on TB research

In this guest post, Mike Watson Frick—TB/HIV program officer at Treatment Action Group (TAG)—writes about the state of tuberculosis (TB) research funding and civil society actions that took place at the recent Union World Conference on Lung Health in Barcelona, Spain.

Read More
HIV Vaccines and Microbicides Resource Tracking Working Group
First-ever conference devoted solely to HIV prevention R&D taking place in uncertain funding environment

Progress toward new tools to prevent HIV infection—including vaccines, microbicides, the use of antiretroviral treatment as HIV prevention, pre-exposure prophylaxis (PrEP), and a host of other options—is being presented and discussed at the inaugural HIV Research for Prevention Conference (HIVR4P) in Cape Town this week.

AVAC
Read More
Making the case for research and innovation for health in the post-2015 development agenda

In this guest post, Claire Wingfield—product development policy officer at PATH—writes about a new paper exploring why research and development (R&D) of high-priority health tools for diseases and conditions affecting low- and middle-income countries (LMICs) should be a critical component of the post-2015 development agenda.

PATH
Read More
Why invest in R&D for HIV, TB and malaria? Because it’s good for global health, and good for Europe

In this post, Eoghan Walsh—communications officer at Deutsche Stiftung Weltbevoelkerung (DSW)—writes about the need for Europe to increase financial and political support for efforts aimed at creating new ways to tackle diseases such as HIV/AIDS, tuberculosis (TB) and malaria.

Read More
A new era for malaria treatment

In this post, PATH Vice President of Product Development, David Kaslow, writes about the first-ever shipment of semisynthetic artemisinin (ssART)—a new type of malaria treatment that marks a significant milestone in the fight against malaria.

Read More
European and African countries meet to advance health technology development for poverty-related diseases

Earlier this week, Anne Hradský—advocacy coordinator for Global Health Research and Development (R&D), Katharina Scheffler—advocacy officer—and others from Deutsche Stiftung Weltbevoelkerung (DSW)—joined other European and African stakeholders for the Seventh European & Developing Countries Clinical Trials Partnerships (EDCTP) Forum in Berlin, Germany.

Read More
Jonathan Torgovnik
Changing the reality of diarrheal disease

When you walk into a diarrheal disease health clinic in a place like Bangladesh, the reality of the disease strikes you immediately.

PATH
Read More
Why R&D matters for maternal and child health

In this guest post, Sarah Alexander—director of external relations for the Global Alliance to Prevent Prematurity and Stillbirth (GAPPS)—writes about the groundswell of momentum surrounding maternal and child health and the role research and development (R&D) can play in helping more babies have a healthy start to life.

Read More
EDCTP2: What it means for European support for global health R&D

In this guest post, Renate Baehr—executive director of Deutsche Stiftung Weltbevoelkerung—writes about the next rendition of the European & Developing Countries Clinical Trials Partnership (EDCTP) and how its expansion will impact more lives in low- and middle-income countries.

Read More
A new Lab to harness the power of innovation

In this guest post, Heather Ignatius—senior policy and advocacy officer at PATH—writes about the new Global Development Lab at the US Agency for International Development (USAID).

PATH
Read More
Seattle Children’s Funds Innovative Research Sites to Study Preterm Birth

This post—written by Sarah Alexander, director of external relations at the Global Alliance to Prevent Prematurity and Stillbirth (GAPPS)—originally appeared in Seattle Children’s On the Pulse blog on March 5th.

Read More
Public-private partnerships: Where have we been and where do we go?

In this guest post, Claire Wingfield—product development policy officer at PATH—writes about a series of dialogues PATH and other partners convened to discuss public-private partnerships for global health product development.

PATH
Read More
TB free breathing in the mines of South Africa: New TB vaccines could transform mining across the region

In this guest post, Kari Stoever, vice president of External Affairs at Aeras, writes about how mine workers are disproportionately affected by tuberculosis (TB) and why there’s an urgent need for new tools against this deadly disease.

Aeras
Read More
The human face of global health R&D: Cynthia Gama and USAID

The US Agency for International Development (USAID) is the nation’s lead foreign assistance agency.

GHTC
Read More
The human face of global health R&D: Brian D’Cruz and USAID

The US Agency for International Development (USAID) is the nation’s lead foreign assistance agency.

GHTC
Read More
Investing in R&D for neglected diseases: Three investment patterns that put lives at risk

In this guest post, Dr. Mary Moran—executive director—and Dr. Penny Farrell—analyst—from Policy Cures shares key findings from the recently released G-FINDER survey.

Policy Cures
Policy Cures
Read More
European action on TB vaccines

In this guest post, Kari Stoever—vice president of External Affairs at Aeras—writes about European support for new vaccines against tuberculosis (TB).

Aeras
Read More
Improving the affordability, availability, and acceptability of health technologies for low- and middle-income countries

In this guest post, Claire Wingfield—product development policy officer at PATH—writes about a new paper she developed for the GHTC that outlines key issues surrounding access to global health products.

PATH
Read More
The end of AIDS requires increased commitments to research

In this guest post, Anupama Dathan—health research assistant for ONE—writes about a new report that examines global commitments to ending the AIDS pandemic.

ONE
Read More
Three key research developments you might have missed from the ASTMH Annual Meeting

In this guest post, Jaclyn Schiff—American Society of Tropical Medicine and Hygiene (ASTMH) Director of Communications—highlights news in global health research presented during the recent ASTMH Annual Meeting.

Read More
The role of HIV research in ending AIDS: New developments in HIV vaccine and prevention science

In this guest post, Emily Donaldson—program coordinator at AVAC: Global Advocacy for HIV Prevention—writes about an upcoming congressional briefing on November 18 that will highlight the latest in HIV/AIDS research and development.

AVAC
Read More
TAG/Hollander Snow Studio
Funding for TB research drops for the first time in eight years

Each year since 2006, TAG has tracked spending on research and development (R&D) for new diagnostics, drugs, and vaccines to improve TB treatment and prevention.

Read More
Vaccinate against the brain drain

In this guest post, Elisabeth Wilhelm, senior media specialist at the International AIDS Vaccine Initiative (IAVI), writes about the need to invest in the next generation of researchers and scientists in sub-Saharan Africa.

Read More
New technologies in family planning

In this guest post, Dr. Judy Manning from the US Agency for International Development (USAID) and Dr. Zeda Rosenberg from the International Partnership for Microbicides (IPM) discuss the need for new and improved contraceptive options for women worldwide.

Read More
New paper examines research funding for diseases and conditions of poverty

In this guest post, Claire Wingfield—product development policy officer at PATH—writes about a new paper she developed for the GHTC that outlines key funding challenges and opportunities for global health research and development (R&D).

PATH
Read More
What comes to mind when you think of drug development?

Ever feel like you can’t see the forest for the trees?

GHTC
Read More
PATH/Elena Pantjushenko
Drug development—It’s not for the faint of heart

Drug discovery and development is a long process. Estimates of the cost to develop a drug up to the point of regulatory approval can range from $150 million to $1.3 billion.

PATH
Read More
PATH/Will Boase
Drug Development 101: A step-by-step guide to drug development

Drug development is a long and complex process.

PATH
Read More
Telling the untold story of tuberculosis

In this guest post, Kari Stoever, vice president of External Affairs at Aeras, writes about a new film series that tells the story of the tuberculosis (TB) pandemic.

Aeras
Read More